about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW
Amber Tong on LinkedIn

author articles

PhI­II dead end for celi­ac drug crush­es pen­ny stock biotech

3 years ago
R&D

As­traZeneca says its $200M cash bet on Io­n­is’ AT­TR drug is pay­ing off — with PhI­II da­ta set­ting up FDA fil­ing

3 years ago
R&D

Lat­est news on thumbs down for Nu­plazid; Amy­lyx’s first ALS ap­proval; Buy­out buzz for trou­bled biotechs; Cannes ...

3 years ago
Weekly

As Covid-re­lat­ed chal­lenges weigh on pa­tient re­cruit­ment, biotech scraps PhI­Ib/III Parkin­son's pro­gram

3 years ago
R&D

New kid on the block: Roger Perl­mut­ter's biotech signs on as an­chor ten­ant to new Bay Area cam­pus

3 years ago
Startups

One year af­ter wrap­ping PhI, Bio­gen drops ALS drug it bought from Karyopharm for $10M cash

3 years ago
Deals

Long-time health­care in­vestor looks to dou­ble num­ber of life sci­ences star­tups in its 'ev­er­green' fund

3 years ago
Financing

Covid-19 roundup: Eu­ro­pean gov­ern­ments push to rene­go­ti­ate vac­cine con­tracts — re­port; As PhII da­ta dis­ap­point, ...

3 years ago
Coronavirus

Bavar­i­an Nordic seals Eu­ro­pean sup­ply deal for small­pox/mon­key­pox vac­cine

3 years ago
Pharma

Ameet Mallik taps fel­low No­var­tis alum to lead busi­ness de­vel­op­ment at ADC Ther­a­peu­tics

3 years ago
People

Up­dat­ed: Al­ny­lam scores OK for sec­ond-gen hAT­TR ther­a­py as the space heats up

3 years ago
Pharma
FDA+

With pan-RAF drug from Take­da, Day One un­veils its first pe­di­atric brain can­cer da­ta. And the mar­ket loves it

3 years ago
R&D

Once promis­ing an al­ter­na­tive shot, Val­neva's Covid-19 sup­ply deal with Eu­rope on verge of col­lapse

3 years ago
Pharma
Coronavirus

Sanofi, GSK keep the ball rolling with da­ta on sec­ond-gen Covid vac­cine can­di­date

3 years ago
R&D
Coronavirus

Pre­view­ing bio­phar­ma trends ahead of #BIO22; Look­ing back at #AS­CO22; Smooth flight for blue­bird?; and more

3 years ago
Weekly

Ex­clu­sive: Pfiz­er vet grabs $25M seed round to 'in­te­grate' ma­chine learn­ing, ge­nomics tech in drug R&D

3 years ago
Financing
Startups

No hu­mans al­lowed: Alex Zha­voronkov adds ro­bot­ic lab to his AI drug dis­cov­ery play as In­sil­i­co un­veils $60M raise

3 years ago
Financing
AI

Lat­est news out of #AS­CO22; GSK, Bris­tol My­ers get M&A go­ing in vac­cines, on­col­o­gy; Roche's pact spot­lights new ...

3 years ago
Weekly

Days af­ter dis­clos­ing tri­al flop, stem cell ther­a­py de­vel­op­er ax­es 70% of work­force while search­ing for cash

3 years ago
People

All in on ear­ly-stage, Qim­ing US bags $260M, re­cruits Atara founder Isaac Ciechanover for Fund III

3 years ago
Financing

'Vac­cines alone are in­suf­fi­cien­t': Mer­ck, Ali­gos work with aca­d­e­m­ic ex­perts to find Covid an­tivi­rals as part of $65M ...

3 years ago
Discovery
Coronavirus

Four years af­ter Roche deal, lit­tle gly­co-fo­cused biotech lands new dis­cov­ery deal with Astel­las

3 years ago
Deals

Will third time be the charm? Lex­i­con fi­nal­ly re­files SGLT2 drug for heart fail­ure

3 years ago
FDA+

GSK bets $3.3B on a buy­out, jump­ing in­to a block­buster show­down with Pfiz­er and Mer­ck

3 years ago
Deals
First page Previous page 29303132333435 Next page Last page
A service from the Financial Times